Amgen Tech Radar: Amgen is deploying artificial intelligence to accelerate therapeutic discovery

Amgen's biggest technology story right now is a massive, enterprise-wide deployment of artificial intelligence and modernized data infrastructure to accelerate revenue growth through faster therapeutic discovery and optimized commercial execution.

Executives explicitly confirmed investing in "modernized AI and data platforms" across their value chain to drive revenue growth and clinical productivity.

Specifically, leadership noted using AI for "molecule design," "trial enrollment," and an "AI protocol authoring tool" to create sharper clinical protocols with fewer inconsistencies.

Additionally, Amgen is focused on manufacturing cost optimization by investing over $600 million in a new science and innovation center that features "advanced automation and digital capabilities".Amgen is also undergoing a major business transformation by shifting toward a direct-to-consumer approach with the launch of "AmgenNow," a direct-to-patient cash-pay program for therapies like Repatha.

While specific underlying software wasn't named, this DTC pivot logically requires deploying new e-commerce payment gateways, consumer-facing digital portals, and specialized direct-to-consumer supply chain tracking technologies.

All sourced directly from Amgen's Q3 and Q4 2025 earnings calls.